Accessibility Menu
Zealand Pharma A/s logo

Zealand Pharma A/s(OTC) ZLDPF

Current Price$45.02
Market Cap$3.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)+259%
5 Year+56%
1 Year-26%
1 Month+5%
Zealand Pharma A/s last closing stock price
MetricPriceDate
Last closeUSD 45.022026-07-24
Zealand Pharma A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.17%USD 44.502026-07-17
1 month+4.97%USD 42.892026-06-24
3 month-5.16%USD 47.472026-04-24
Year to date-37.12%USD 71.602025-12-31
1 year-26.26%USD 61.062025-07-24
3 year+34.71%USD 33.422023-07-25
5 year+55.67%USD 28.922021-06-24
Since inception+258.69%USD 12.552012-02-14

Zealand Pharma A/s Financials at a Glance

Market Cap

$3.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 9.24B

Net Income (TTM)

DKK 6.40B

EPS (TTM)

$13.43

P/E Ratio

3.28

Dividend

$0.00

Beta (Volatility)

0.37 (Low)

Price

$45.02

Volume

210

Open

$45.02

Previous Close

$45.02

Daily Range

$45.02 - $45.02

52-Week Range

$35.93 - $83.12

Estimated Earnings Date

Aug 13, 2026

ZLDPF News

Person Computer 5.jpg

A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.

Bram BerkowitzJun 8, 2026
3 investors gather around a laptop

2 Weight Loss Stocks That Are Screaming Buys in December

Alex CarchidiDec 15, 2024
researcher works at lab bench

GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom

Alex CarchidiOct 13, 2024
two investors put sticky notes on glass wall

This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money

Alex CarchidiAug 25, 2024
doctors with investors

This Rising Biotech Is a Fantastic Weight-Loss Stock to Buy Now

Alex CarchidiAug 21, 2024
Investor at home looking at multiple charts.

Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio

David Jagielski, CPAJul 5, 2024
A team of scientists reviewing results in a lab.

Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss Stock.

David Jagielski, CPAMar 14, 2024

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zealand Pharma A/s

Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, focused on the entire lifecycle of peptide-based medicines. The company specializes in developing treatments for gastrointestinal and metabolic disorders, with a strong emphasis on addressing unmet medical needs.

Products and Services
  • Offers lixisenatide, marketed as Adlyxin and Lyxumia
  • Commercializes Dasiglucagon for severe hypoglycemia and related conditions
  • Maintains a robust pipeline, including glepaglutide for short bowel syndrome
Growth Outlook
  • Dasiglucagon is advancing through Phase III trials for congenital hyperinsulinism
  • Strategic collaborations with major pharmaceutical companies enhance development capabilities
  • Focus on automated diabetes management systems positions the company for future growth
Financial Highlights
  • Recent quarterly revenue of 34.04 million DKK, showing potential for growth
  • TTM net profit margin stands at 69.2%, indicating strong profitability
  • Current ratio of 37.17 suggests excellent liquidity and financial health
Zealand Pharma A/S operates in a dynamic sector with a commitment to innovation in peptide-based therapies. The company's current offerings, including Dasiglucagon and lixisenatide, address critical health issues, while its development pipeline promises future advancements. The strategic partnerships with leading pharmaceutical firms further bolster its position in the market. Recent financial performance indicates a solid foundation, with a strong net profit margin and liquidity, making it an intriguing option for investors interested in the biotechnology sector.
AI Generated • Jun 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

544

CEO

Adam Sinding Steensberg, MD, MBA

Website

www.zealandpharma.com

Headquarters

Copenhagen, 2860, DK

ZLDPF Financials

Key Financial Metrics (TTM)

Gross Margin

99.72%

Operating Margin

73.88%

Net Income Margin

69.22%

Return on Equity

42.59%

Return on Capital

46.96%

Return on Assets

41.80%

Earnings Yield

30.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

70.71M

Volume

210

Avg. Volume

833.758

Financials (TTM)

Gross Profit

DKK 9.22B

Operating Income

DKK 6.83B

EBITDA

DKK 6.74B

Operating Cash Flow

DKK 6.74B

Capital Expenditure

-DKK 34.12M

Free Cash Flow

DKK 6.70B

Cash & ST Invst.

DKK 14.48B

Total Debt

DKK 414.43M

Zealand Pharma A/s Performance Analysis

Zealand Pharma A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31DKK 14,690,202-14.8%
20232023-12-31DKK 49,737,397238.6%
20242024-12-31DKK 9,091,613-81.7%
20252025-12-31DKK 1,393,445,09915226.7%
Zealand Pharma A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30112212.0%
Q32025-09-30-99.5%
Q42025-12-3138.7%
Q12026-03-31-50.5%
Zealand Pharma A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31DKK -2.955.5%
20232023-12-31DKK -1.80-38.9%
20242024-12-31DKK -2.3630.5%
20252025-12-31DKK 13.64N/A
Zealand Pharma A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-302323.4%
Q32025-09-30-100.9%
Q42025-12-31-493.3%
Q12026-03-31-4.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

DKK 34.04M

+320.6%

Gross Profit

DKK 24.02M

+212.5%

Gross Margin

70.59%

N/A

Market Cap

$3.18BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.85M

N/A

Employees

544

N/A

Net Income

-DKK 394.41M

-17.6%

EBITDA

-DKK 529.55M

-63.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

DKK 14.48B

+69.5%

Total Debt

DKK 414.43M

+5.0%

Accounts Receivable

DKK 239.25M

+59.6%

Inventory

DKK 0.00

-100.0%

Long Term Debt

DKK 385.40M

+1.9%

Short Term Debt

DKK 58.03M

+252.9%

Return on Assets

41.80%

N/A

Return on Invested Capital

45.83%

N/A

Free Cash Flow

-DKK 682.71M

-34.0%

Operating Cash Flow

-DKK 672.70M

-34.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CAMRFCamurus AB
$58.51+0.00%
HKMPFHikma Pharmaceuticals PLC
$20.37+0.00%
HKMPYHikma Pharmaceuticals PLC
$41.27+0.00%
AKBLFALK-Abelló A/S
$37.92+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
TAT&T
$24.13+0.05%

Questions About ZLDPF

What is the current price of Zealand Pharma A/s?

Zealand Pharma A/s is trading at $45.02 per share.

What is the 52-week range for Zealand Pharma A/s?

Over the past 52 weeks, Zealand Pharma A/s has traded between $35.93 and $83.12.

How much debt does Zealand Pharma A/s have?

As of the most recent reporting period, Zealand Pharma A/s reported total debt of DKK 63.84M.

How much cash does Zealand Pharma A/s have on hand?

Zealand Pharma A/s reported DKK 593.49M in cash and cash equivalents in its most recent financial results.

What is Zealand Pharma A/s’s dividend yield?

Zealand Pharma A/s does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services